| 摘要 |
There is disclosed <SL> <LI>(i) a method of modifying the level of a cytokine and <LI>(ii) a method of testing for a modification in the level of a cytokine, </SL> which comprises contacting a compound, or a pharmaceutically acceptable salt thereof, with a cell (in vivo, ex vivo or in vitro), wherein the compound comprises: ```at least one monosaccharide subunit comprising a directly bonded =NR or =NR2+ ```group, or a glycosidic -NR2, -NR3+, ```wherein R is H, a monosaccharide subunit or hydrocarbyl group ```or 2 or 3 R groups, together with the nitrogen to which they are attached, form a ```monosaccharide subunit or cyclic hydrocarbyl group; ```each hydrocarbyl group, which includes acyl, is optionally substituted and optionally ```includes one or more hetero atoms in its hydrocarbon skeleton; ```each monosaccharide subunit is optionally modified (as defined in the application) ```and optionally substituted, and polysaccharide, oligosaccharide, peptide and protein derivatives comprising such compounds, and mixtures thereof, subject to various provisos defined in claims 1, 7, 13, 19, 44 and 89. Such compounds also find application in the treatment and/or prevention of inflammation and autoimmune disorders. There is disclosed a method of modifying the level of VEGF (in vivo, ex vivo or in vitro) contacting a cell with the compound PHA (phyrohaemagglutinin), or a structurally similar protein. |
